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ABSTRACT Toxoplasma gondii is a protozoan parasite of great importance to hu-
man and animal health. In the host, this obligate intracellular parasite persists as a
tissue cyst that is imperceptible to the immune response and unaffected by current
therapies. The tissue cysts facilitate transmission through predation and give rise to
chronic cycles of toxoplasmosis in immunocompromised patients. Transcriptional
changes accompany conversion of the rapidly replicating tachyzoites into the en-
cysted bradyzoites, and yet the mechanisms underlying these alterations in gene ex-
pression are not well deﬁned. Here we show that AP2IX-4 is a nuclear protein exclu-
sively expressed in tachyzoites and bradyzoites undergoing division. Knockout of
AP2IX-4 had no discernible effect on tachyzoite replication but resulted in a reduced
frequency of tissue cyst formation following alkaline stress induction—a defect that
is reversible by complementation. AP2IX-4 has a complex role in regulating brady-
zoite gene expression, as the levels of many bradyzoite mRNAs dramatically in-
creased beyond those seen under conditions of normal stress induction in AP2IX-4
knockout parasites exposed to alkaline media. The loss of AP2IX-4 also resulted in a
modest virulence defect and reduced cyst burden in chronically infected mice,
which was reversed by complementation. These ﬁndings illustrate that the transcrip-
tional mechanisms responsible for tissue cyst development operate across the inter-
mediate life cycle from the dividing tachyzoite to the dormant bradyzoite.
IMPORTANCE Toxoplasma gondii is a single-celled parasite that persists in its host
as a transmissible tissue cyst. How the parasite converts from its replicative form to
the bradyzoites housed in tissue cysts is not well understood, but the process clearly
involves changes in gene expression. Here we report that parasites lacking a cell
cycle-regulated transcription factor called AP2IX-4 display reduced frequencies of tis-
sue cyst formation in culture and in a mouse model of infection. Parasites missing
AP2IX-4 lose the ability to regulate bradyzoite genes during tissue cyst develop-
ment. Expressed in developing bradyzoites still undergoing division, AP2IX-4 may
serve as a useful marker in the study of transitional forms of the parasite.
KEYWORDS ApiAP2, apicomplexan parasites, differentiation, gene expression,
intracellular parasites, transcription
Toxoplasma gondii is an obligate intracellular protozoan parasite that has infected upto one-third of the world’s population (1). A key factor contributing to this parasite’s
widespread seroprevalence is its ability to transmit to new hosts through multiple
routes (2). Felines are the deﬁnitive hosts that release infectious oocysts into the
environment following infection. Oocysts, which are stable in the environment for up
to 1 year, can be picked up by any warm-blooded vertebrate from contaminated soil or
water (3). Upon ingestion, the sporozoites inside the oocysts are released, developing
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into tachyzoites capable of infecting any nucleated cell (4). During an initial infection,
Toxoplasma is also capable of crossing the placenta and potentially infecting the
unborn fetus, resulting in spontaneous abortion or birth defects (5). Tachyzoites
replicate asexually and can lead to the destruction of the host cell; alternatively,
tachyzoites can differentiate into bradyzoites. Bradyzoite development is accompanied
by slowed parasite growth and the formation of tissue cysts that can persist for long
periods, perhaps for the lifetime of the host. New hosts can become infected when
these tissue cysts are consumed through predation, which includes humans who eat
raw or undercooked meat containing tissue cysts (2). Life-threatening episodes of acute
toxoplasmosis most commonly arise in patients with compromised immune systems,
such as in cases of HIV/AIDS, cancer chemotherapy, or organ transplantation, as a result
of newly acquired or recrudescent infection (6). A better understanding of the molec-
ular mechanisms that drive interconversion between tachyzoites and bradyzoites is
required to manage transmission and pathogenesis of Toxoplasma.
Many studies have documented genes that are exclusively expressed in either
tachyzoites or bradyzoites, suggesting that gene expression mechanisms play a major
role in coordinating developmental transitions in Toxoplasma. Studies of stage-speciﬁc
promoters revealed that conventional cis-acting mechanisms operate to regulate de-
velopmental gene expression during tissue cyst formation (7). The members of the
principal class of transcription factors likely to work through these cis-acting promoter
elements share features with the Apetala-2 (AP2) family in plants (8). In plants, the AP2
domain is composed of an ~60-amino-acid DNA-binding domain; plant factors with a
single AP2 domain are linked to stress responses, whereas those with tandem AP2
domains are linked to plant development (9). However, more recent analyses of AP2
domains have been performed on additional species, including prokaryotes and free-
living photosynthetic algae closely related to apicomplexan parasites. These data
suggest that apicomplexan AP2 (ApiAP2) proteins originated in bacteria and expanded
in myzozoans independently of those in plants, prior to the split between the Apicom-
plexa and chromerids (10).
Numerous ApiAP2 factors found in Plasmodium spp., Toxoplasma, Cryptosporidium
parvum, and Theileria annulata are capable of binding speciﬁc DNA motifs (11–14), and
several have been implicated as transcription factors involved in stage-speciﬁc gene
regulation. In the rodent malaria parasite Plasmodium berghei, AP2-O activates gene
expression in ookinetes (15), AP2-Sp regulates gene expression during the sporozoite
stage (16), and AP2-L contributes to liver-stage development (17). PbAP2-G and
PbAP2-G2 appear to work in conjunction to orchestrate transition of asexual blood-
stage parasites to gametocytes (18). While PbAP2-G2 represses genes that are required
for the proliferation of the asexual stage, PbAP2-G and its orthologue in Plasmodium
falciparum function as master regulators that are essential for sexual stage develop-
ment (19, 20). Those studies support the concept that transcriptional switches underlie
developmental transitions between parasite life cycle stages. The work by Kafsack et al.
also supports a stochastic model for gametocyte development, whereby spontaneous
activation of PfAP2-G in some asexual stage parasites prompts transition to the sexual
stage (20).
There are 67 predicted proteins in the Toxoplasma genome that harbor one or more
AP2 domains (see ToxoDB.org), more than double the number found in Plasmodium
spp. (21). In Toxoplasma, ApiAP2 factors have been found in association with chromatin
remodeling machinery (22), and genetic studies have supported the idea of roles in
regulating transcription in the context of developmental transitions from tachyzoites to
bradyzoites (23–25). AP2IX-9, which is a stress-induced ApiAP2 factor, binds to cis-
regulatory elements of bradyzoite promoters and operates as a repressor of bradyzoite
development (23). In contrast, the AP2IV-3 stress-induced factor is an activator of
bradyzoite gene expression and parasites lacking this factor display a reduced capacity
to form tissue cysts in vitro (26). A knockout of AP2XI-4 impaired the activation of genes
expressed during stress-induced differentiation and resulted in reduced cyst burdens in
infected mice (24). Finally, AP2XII-6 was disrupted in a bradyzoite differentiation mutant
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generated by insertional mutagenesis (25). To date, no master ApiAP2 factor has been
identiﬁed in Toxoplasma that drives the unique transcriptome of any life cycle stage.
Here, we investigated the function of AP2IX-4, an ApiAP2 whose mRNA is upregu-
lated during bradyzoite differentiation and exhibits cell cycle regulation. We show that
AP2IX-4 protein is expressed in the parasite nucleus during the S/M phase. Surprisingly,
genetic ablation of AP2IX-4 has no discernible effects on tachyzoites, and yet the
knockout shows a reduced capacity to form tissue cysts in vitro and in vivo. These
defects in developmental competency are reversed in a complemented knockout.
AP2IX-4 is expressed in a subpopulation of bradyzoites that are undergoing division
within a tissue cyst and acts to repress bradyzoite-associated genes. These ﬁndings
underscore the complexity of the transcriptional program driving developmental tran-
sition to the bradyzoite stage and suggest that AP2IX-4 helps control the competing
needs of parasite replication and tissue cyst formation.
RESULTS
AP2IX-4 is expressed in the nucleus during the S-M phase of the cell cycle. A
previous study of predicted Toxoplasma ApiAP2 proteins revealed that AP2IX-4
(TGME49_288950) is 1 of 7 ApiAP2 genes whose mRNA is upregulated during alkaline
stress (23) and exhibits cell cycle regulation in the tachyzoite (21). AP2IX-4 mRNA is one
of the few ApiAP2 factors expressed at higher levels in day 21 tissue cysts puriﬁed from
mice, and it is also robustly expressed during sporozoite meiosis (26). The single-exon
AP2IX-4 gene is predicted to encode a 104-kDa protein consisting of 951 amino acids
that harbors a single AP2 domain; no other protein domains were detected with SMART
or InterPro protein sequence analyzers (27, 28).
We generated an endogenously epitope-tagged version of AP2IX-4 to conﬁrm its
size and expression pattern at the protein level and also to determine protein local-
ization. RHku80::HXGPRT (RHQ) parasites were engineered to express native AP2IX-4
fused to a hemagglutinin (3xHA) tag at its C terminus (AP2IX-4HA) (Fig. 1A). Western
blotting of tachyzoite lysate showed that AP2IX-4HA migrates as a single band at the
expected size (Fig. 1B). Immunoﬂuorescence assays (IFAs) were performed to detect
subcellular localization and expression throughout the tachyzoite cell cycle while using
the inner membrane complex-3 (IMC3) antibody to help delineate the cell cycle stages
(29). AP2IX-4HA protein was undetectable in the G1 phase, appeared during the S-M
stages, then decreased in expression during cytokinesis (Fig. 1C), consistent with its
reported mRNA proﬁle (21). Since the IMC3 staining pattern does not distinguish
between the G1 and S phases of the cell cycle, we quantiﬁed the proportion of vacuoles
in G1/S with no HA signal with respect to those in G1/S with HA signal and in M/C with
HA signal. The ﬁndings showed the proportions to be approximately 60%, 30%, and
10%, respectively, which is consistent with the distribution of G1, S, and M/C cell cycle
phases in an asynchronous tachyzoite population (Fig. 1D) (30). The IFA results also
indicated that AP2IX-4HA was exclusively present in the parasite nucleus when ex-
pressed (Fig. 1C).
AP2IX-4 is dispensable for tachyzoite replication in vitro. To investigate the
function of AP2IX-4, we generated gene knockouts in RHQ and Pruku80hxgprt (PruQ)
strains by replacing the genomic coding sequence (CDS) with a selectable marker
dihydrofolate reductase-thymidylate synthase (DHFR*-TS) via double homologous re-
combination (Fig. 2A). Genomic PCRs were performed to screen transfected clones
isolated by limiting dilution. Figure 2B shows the results, conﬁrming successful allelic
replacement of the AP2IX-4 gene in the PruQ background (named the ap2IX-4
mutant). Reverse transcription-PCR (RT-PCR) was performed on mRNA harvested from
ap2IX-4 parasites to verify loss of transcript (Fig. 2B). Parasite replication rates were
determined using a doubling assay (Fig. 2C), and viability was examined using a plaque
assay (Fig. 2D). Neither assay revealed a signiﬁcant difference in the levels of in vitro
growth between parental and ap2IX-4 parasites in the PruQ strain (Fig. 2C and D) or
the RHQ strain (data not shown). These results suggest that, despite its appearance
during the S-M stages of the cell cycle, AP2IX-4 is not required for tachyzoite replication.
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AP2IX-4 is present in bradyzoites and required for efﬁcient cyst formation in
vitro. Previous studies indicated that levels of AP2IX-4 mRNA increase during brady-
zoite differentiation in vitro and that elevated levels of AP2IX-4 transcripts are present
during the chronic stage of infection in mice (21, 31). To examine the function of
AP2IX-4 in bradyzoites, we complemented the PruQap2IX-4 parasites by targeting a
cDNA-derived version of AP2IX-4 tagged with HA at its C terminus to be under the
control of the native AP2IX-4 promoter (PruQap2IX-4::AP2IX-4HA; Fig. 3A). Genomic
PCRs conﬁrmed integration of the complementation construct at the disrupted ap2IX-4
locus (Fig. 3B), and Western blot analysis conﬁrmed the expected size of the AP2IX-4HA
protein (Fig. 3C). Furthermore, the AP2IX-4HA protein in the complemented knockout
localized properly to the parasite nucleus during S-M phases (Fig. 3D), matching the
pattern that we observed for native protein in RH parasites (Fig. 1C). The proportions
of vacuoles in G1/S with no HA signal relative to those in G1/S with HA signal and in M/C
with HA signal were approximately 60%, 30%, and 10%, respectively (Fig. 3E), consistent
with observations made in the type I strain (Fig. 1D). Together, these data conﬁrm the
FIG 1 Characterization of AP2IX-4 protein expression. (A) Schematic showing the strategy used to generate parasites expressing AP2IX-4
tagged at the C terminus with 3xHA epitopes (AP2IX-4HA) in RHQ parasites. The AP2IX-4 genomic locus is aligned with the pLIC-3xHA
construct used for endogenous tagging via single homologous recombination. The construct contains a 1,514-bp homology region and
a DHFR*-TS drug selection cassette. UTR, untranscribed region. (B) Western blot (WB) of parental RHQ and AP2IX-4HA parasites probed with
anti-HA antibody. Anti--tubulin was used to verify the presence of parasite protein. kD, kilodaltons. (C) IFAs performed on AP2IX-4HA
tachyzoites using anti-HA (green). To monitor cell cycle phases, parasites were costained with anti-IMC3 (red) and DAPI (blue). G1, gap
phase; S, synthesis phase; M, mitotic phase; C, cytokinesis. Scale bar, 3 m. (D) Quantiﬁcation of the proportion of parasite vacuoles (of
100) in the asynchronous population of AP2IX-4HA parasites exhibiting G1/S IMC3 staining with absence of HA signal (G1/S HA-), G1/S IMC3
staining with positive HA signal (G1/S HA), or M/C staining with positive HA signal (M/C). Error bars represent standard deviations of
results from 3 independent experiments.
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ﬁdelity of the complemented knockout and uncover no differences in localization or
cell cycle regulation of AP2IX-4 between type I and type II strains.
Taking advantage of this HA-tagged version of AP2IX-4 in the developmentally
competent type II strain, we monitored protein expression by IFA during alkaline stress
(pH 8.2), a well-characterized inducer of tissue cyst development in vitro (32). The PruQ
strain also contains a green ﬂuorescent protein (GFP) reporter driven by the bradyzoite-
speciﬁc LDH2 promoter (33, 34). Under alkaline stress bradyzoite induction conditions,
expression of AP2IX-4HA was heterogeneous within the population of bradyzoites
housed in individual cysts (Fig. 4A). Comparing the number of AP2IX-4HA-positive
parasites to the total number of parasites within developing tissue cysts (among 50
random cysts in 3 independent replicates), we found that only 13% were expressing
AP2IX-4HA at 2 and 4 days postinduction. In contrast, 37% of tachyzoites expressed
AP2IX-4HA. Costaining for IMC3 revealed that GFP-positive bradyzoites express-
ing AP2IX-4HA were in the process of dividing, revealing that AP2IX-4HA expression
continued to be regulated by the cell cycle during encystation (Fig. 4B). Loss of
AP2IX-4 does not appear to have had a signiﬁcant impact on the number of
FIG 2 Generation of PruQΔap2IX-4 parasites. (A) Schematic illustrating the generation of the AP2IX-4 knockout by allelic replacement with
a DHFR*-TS minigene. (B) Genomic PCRs were performed with the indicated primers (A to G) to verify replacement of the AP2IX-4 genomic
locus with the DHFR*-TS minigene. RT-PCR performed with primers B and E conﬁrmed the absence of AP2IX-4 transcripts in PruQap2IX-4
parasites. Primers for GAPDH were used as a positive control for the RNA preparation. (C) Representative doubling assay showing the
number of parasites/vacuole at 24- and 36-h time points postinfection for parental PruQ versus PruQap2IX-4 parasites. Three
independent assays were performed with similar results. P 0.05 (unpaired two-tailed Student’s t test). (D) Plaque assays were performed
to compare the in vitro viability of PruQ parasites to that of PruQap2IX-4 parasites. Three independent assays were performed with similar
results. P  0.98 (unpaired two-tailed Student’s t test).
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parasites undergoing division at day 4 of bradyzoite induction; the proportions of
dividing parasites as assessed by IMC3 staining of 50 random cysts were 7.6% for
PruQ parasites and 6.5% for PruQap2IX-4 parasites.
We next examined the frequency of bradyzoite cyst development in parental PruQ
and PruQap2IX-4 parasites in response to alkaline stress, as determined by the
number of vacuoles staining positive for cyst wall protein binding Dolichos lectin. After
FIG 3 Complementation of the AP2IX-4 knockout. (A) Schematic illustrating the generation of the complemented knockout (ap2IX-4::
AP2IX-4HA). A cDNA-derived version of AP2IX-4 tagged at the C terminus with 3xHA (complementation construct) was targeted to the
ablated genomic locus in ap2IX-4 parasites. (B) Genomic PCRs were performed with the indicated primer pairs to conﬁrm proper
integration of the complementation construct into Δap2IX-4 parasites. Primers corresponding to GAPDH were used as a positive control
of the DNA preparation. (C) Western blot of ap2IX-4 and ap2IX-4::AP2IX-4HA parasites with anti-HA, using anti--tubulin as a control to
verify the presence of parasite protein. (D) IFAs were performed on ap2IX-4::AP2IX-4HA tachyzoites as described for Fig. 1C. (E)
Quantiﬁcation of the proportion of parasite vacuoles (of 100) in the asynchronous population of AP2IX-4HA parasites performed as
described for Fig. 1D.
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4 days in alkaline pH, 73% of parental PruQ parasites converted into bradyzoites, but
this was reduced to 46% in parasites lacking AP2IX-4 (Fig. 5). Complementation of the
AP2IX-4 knockout parasites restored the rate of bradyzoite cyst formation to levels
matching wild-type PruQ strain levels (Fig. 5). These data show that AP2IX-4HA contin-
ues to be expressed in a cell cycle-regulated manner post-bradyzoite induction and
that its ablation impairs the frequency at which cysts form in vitro.
Loss of AP2IX-4 results in dysregulated gene expression. To assess the impact of
AP2IX-4 on gene expression, RNA was harvested from parental PruQ and PruQap2IX-4
FIG 4 Expression of AP2IX-4 in developing bradyzoites in vitro. (A) IFAs were performed on ap2IX-4::AP2IX-4HA
parasites during the tachyzoite and developing bradyzoite stages for up to 8 days (8d) in alkaline pH. FITC-
conjugated Dolichos lectin was used to visualize bradyzoite cyst walls (the LDH2-GFP reporter also appears in
bradyzoites in this channel). AP2IX-4ha protein was visualized using anti-HA (red), and DAPI (blue) was used to stain
DNA. The percentage of parasites expressing AP2IX-4HA within 50 random vacuoles (%HA) was recorded; note
that it was not possible to accurately discern the total number of parasites in tissue cysts beyond 4 days
postinduction. ND, not determined. Values represent the averages and standard deviations of results from 3
independent experiments. (B) IFAs performed with anti-IMC3 antibody (yellow) on ap2IX-4::AP2IX-4HA parasites
following 4 days in alkaline pH. The LDH2-GFP reporter (green) identiﬁes bradyzoites. AP2IX-4ha protein was
visualized using anti-HA (red). Arrows point to budding daughter cells in dividing parasites expressing AP2IX-4HA.
Scale bar, 3 m.
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parasites cultured under tachyzoite (pH 7) or bradyzoite-inducing (pH 8.2) conditions
for 2 days and hybridized onto ToxoGeneChip microarrays (35). Under tachyzoite
conditions, very few genes were dysregulated in the knockout (see Table S2 in the
supplemental material). In contrast to the results seen under tachyzoite culture condi-
tions, 119 genes were differentially expressed 2-fold in the knockout under brady-
zoite induction conditions: 64 were downregulated in the PruQap2IX-4 parasites
compared to the parental parasites, while 55 were upregulated (Table S3). Approxi-
mately 89% of these genes were complemented in knockout parasites in which AP2IX-4
expression had been restored. Table 1 shows a representative group of genes that were
rescued by complementation (the complete list of complemented genes is in Table S3).
Four bradyzoite-associated genes, including those encoding enoyl-coenzyme A (enoyl-
CoA) hydratase/isomerase and hypothetical proteins TGME49_205680, TGME49_287040,
and TGME49_306270, were downregulated in the knockout following stress (Table 1).
Enoyl-CoA hydratase/isomerase, along with a MoeA domain-containing protein (in-
volved in biosynthesis of molybdopterin), was downregulated in the AP2IX-4 knockout
under both tachyzoite and bradyzoite-inducing conditions. Strikingly, the majority of
genes showing enhanced expression in the AP2IX-4 knockout upon stress were those
encoding well-established bradyzoite-associated proteins such as ENO1, BAG1, PMA1,
B-NTPase, LDH2, DnaK-TPR, SAG2C, and MCP4 (Table 1).
Findings from the transcriptomic analysis suggest that AP2IX-4 leads to aberrant
gene expression that is more pronounced following alkaline stress treatment. The
overall pattern that emerged suggests that bradyzoite-associated genes generally see
enhanced activation in the knockout following stress. To determine if the dysregulated
gene expression caused by ablation of AP2IX-4 has consequences on pathogenesis, we
examined acute and chronic infection in a mouse model.
Analysis of PruQap2IX-4 in mouse models of acute and chronic toxoplasmo-
sis. To determine if the loss of AP2IX-4 impacts virulence in vivo, BALB/c mice (8 per
group) were infected with 107, 106, or 105 parental PruQ, PruQap2IX-4, or PruQap2IX-
4::AP2IX-4HA parasites and monitored for 14 days. A dose of 107 parasites was equally
lethal for all strains injected into the mice, whereas all mice infected with 105 parasites
survived (Fig. 6A). Three of the 8 mice infected with either parental or PruQap2IX-4::
AP2IX-4HA parasites survived a dosage of 106; however, all 8 mice infected with 106 of
the PruQap2IX-4 parasites survived (Fig. 6A). Despite its being dispensable for
FIG 5 Loss of AP2IX-4 results in lower frequency of bradyzoite cyst formation in vitro. Parental PruQ,
ap2IX-4, and ap2IX-4::AP2IX-4HA parasites were cultured in alkaline medium for 4 days and then
stained with Dolichos lectin to visualize tissue cyst walls. For each sample, 100 random vacuoles were
surveyed for the presence or absence of lectin staining to determine the frequency of cyst formation. n
4 for parental and ap2IX-4; n 3 for ap2IX-4::AP2IX-4HA. *, P 0.04; **, P 0.006 (unpaired two-tailed
Student’s t test). Error bars represent standard errors of the means.
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TABLE 1 Differentially expressed genes in ap2IX-4 and ap2IX-4::AP2IX-4HA parasites under bradyzoite induction conditionsa
Accession no. Annotation
FC
PruQap2IX-4 mutant
versus PruQ parental strain
ap2IX-4::AP2IX-4HA mutant
versus PruQap2IX-4 mutant
Downregulated genes
TGME49_288950 AP2IX-4 38.1 22.00
TGME49_319890 Hypothetical protein 7.6 1.8
TGME49_293480 MoeA N-terminal region (domain I and II) domain-
containing protein
7.4 3.4
TGME49_243940 Hypothetical protein 7.0 1.8
TGME49_204050 Subtilisin SUB1 (SUB1) 4.9 1.7
TGME49_317705 Enoyl-CoA hydratase/isomerase 3.8 2.2
TGME49_297910 Hypothetical protein 3.7 2.1
TGME49_256792 Hypothetical protein 3.6 2.1
TGME49_217400 Hypothetical protein 3.5 3.2
TGME49_205680 Hypothetical protein 3.2 1.7
TGME49_287040 Hypothetical protein 3.1 1.8
TGME49_306270 Hypothetical protein 3.0 1.7
TGME49_280500 Inorganic anion transporter, sulfate permease
(SulP) family protein
2.6 2.2
TGME49_261250 Histone H2A1 2.6 1.7
TGME49_240090 Rhoptry kinase family protein ROP34, putative 2.5 1.6
TGME49_214190 SRS46 2.3 1.6
TGME49_239260 Histone H4 2.2 1.7
TGME49_261240 Histone H3 2.1 2.4
TGME49_305160 Histone H2Ba 2.0 2.9
TGME49_255060 Cytochrome b (N-terminal)/b6/petB subfamily
protein
2.0 3.9
Upregulated genes
TGME49_268860 ENO1 10.2 2.3
TGME49_312905 Hypothetical protein 9.7 7.3
TGME49_209755 Hypothetical protein 7.0 2.5
TGME49_259020 BAG1 5.7 1.6
TGME49_293790 Hypothetical protein 4.9 2.1
TGME49_278080 Toxoplasma gondii family A protein 4.9 1.7
TGME49_216140 Tetratricopeptide repeat-containing protein 4.4 1.8
TGME49_252640 P-type ATPase PMA1 4.4 1.7
TGME49_225290 GDA1/CD39 (nucleoside phosphatase) (B-NTPase) 4.1 2.1
TGME49_315560 ATP-binding cassette G family transporter ABCG77 4.0 1.5
TGME49_291040 Lactate dehydrogenase LDH2 (LDH2) 4.0 1.6
TGME49_202020 DnaK-tetratricopeptide repeat (DnaK-TPR) 3.9 1.8
TGME49_221550 CMGC kinase, MAPK family, MEK kinase related 3.7 1.9
TGME49_292260 SAG-related sequence SRS36B (SAG5D) 3.6 1.9
TGME49_266700 Hypothetical protein 3.5 1.9
TGME49_240470 Hypothetical protein 3.2 1.7
TGME49_207160 SAG-related sequence SRS49D (SAG2C) 3.1 2.2
TGME49_267470 Cold-shock DNA-binding domain-containing
protein
3.1 1.7
TGME49_253680 Hypothetical protein 3.0 1.5
TGME49_208730 Microneme protein, putative (MCP4) 3.0 1.6
TGME49_207150 SAG-related sequence SRS49C (SAG2D) 2.9 1.9
TGME49_287960 Hypothetical protein 2.7 1.6
TGME49_218470 Protein disulﬁde-isomerase 2.6 1.9
TGME49_253710 Hypothetical protein 2.6 1.7
TGME49_306338 Dynein gamma chain, ﬂagellar outer arm, putative 2.5 1.9
TGME49_243720 Peroxisomal biogenesis factor PEX11 (PEX11) 2.5 1.9
TGME49_259960 Nucleoside diphosphatase 2.4 1.5
TGME49_312905 Hypothetical protein 2.4 2.0
TGME49_314250 Bradyzoite rhoptry protein BRP1 (BRP1) 2.4 1.8
TGME49_253330 Rhoptry kinase family protein (BPK1) 2.3 1.5
TGME49_224830 Hypothetical protein 2.2 1.5
TGME49_221840 Hypothetical protein 2.2 1.5
TGME49_311370 Methylmalonate-semialdehyde dehydrogenase 2.1 2.0
TGME49_213460 Hypothetical protein 2.0 1.7
TGME49_266900 Cyclin, N-terminal domain-containing protein 2.0 1.6
aDifferentially expressed genes were deﬁned as those corresponding to a fold change (FC) difference of 2. Genes that were previously found to be upregulated
during bradyzoite induction are highlighted in gray (see Materials and Methods).
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tachyzoite replication in vitro, these data suggest that loss of AP2IX-4 results in a
modest virulence defect in vivo.
We also analyzed the brain cyst burden in BALB/c mice infected with 106 parental
PruQ, PruQap2IX-4, or PruQap2IX-4::AP2IX-4HA parasites at 35 days postinfection.
Mice infected with parental parasites contained an average of 169  27 brain cysts,
while those infected with PruQap2IX-4 yielded a signiﬁcantly reduced average of 91
17 brain cysts (P  0.03; Fig. 6B). Complementation of PruQap2IX-4 reversed the
phenotype, producing an average of 176  44 brain cysts (Fig. 6B). The restoration of
parent levels of cyst formation following complementation indicates successful genetic
rescue of PruQap2IX-4 defects. This experiment was repeated to ensure reproducibil-
ity and yielded a similar trend, with parental parasites producing 4,021  1,488 brain
cysts and PruQap2IX-4 parasites producing only 487  31 brain cysts (P  0.02; data
not shown). Consistent with the reduced frequency of bradyzoite development noted
in vitro, these data suggest that loss of AP2IX-4 also results in decreased bradyzoite
frequency in vivo.
DISCUSSION
The establishment of tissue cysts within host cells is essential for Toxoplasma
transmission and is the underlying cause of chronic infection in patients. Tissue cyst
formation requires that tachyzoites slow their replication rate, which is associated with
FIG 6 Virulence and cyst burden in mice infected with Δap2IX-4 parasites. (A) Mice (n 8 per group) were infected
with 107, 106, or 105 parental, Δap2IX-4, or Δap2IX-4::AP2IX-4HA parasites and monitored over 14 days for survival.
*, P 0.01; **, P 0.02 (log-rank test). (B) Mice were infected with 106 of the designated parasites (n 4 per group)
and allowed to progress to chronic infection for 35 days before brain cyst burden was assessed. *, P  0.03
(unpaired one-tailed Student’s t test).
Huang et al.
March/April 2017 Volume 2 Issue 2 e00054-17 msphere.asm.org 10
a lengthening of the G1 phase (36). A complete inhibition of tachyzoite growth blocks
bradyzoite development (37), while no fast-growing bradyzoite has ever been identi-
ﬁed. These observations suggest that formation of bradyzoites is a stepwise process
involving growth mechanisms, although how many steps and what molecular mech-
anisms are involved is not understood. At a minimum, tissue cyst development involves
a slow-growing prebradyzoite that expresses bradyzoite antigens and a mature stage
that is nonreplicative and may be required for transmission (13, 38). Deﬁning the
bradyzoite developmental pathway is hampered by its heterologous nature. Unlike the
tachyzoite stage, which shows striking synchronous intravacuolar behavior, parasites
undergoing bradyzoite development are largely asynchronous and tissue cysts contain
a highly variable number of bradyzoites (38). These challenges have contributed to the
lack of mechanistic knowledge of how tissue cysts are formed.
Like all ApiAP2 factors characterized, AP2IX-4 is present exclusively in the nucleus.
AP2IX-4 also belongs to the set of cyclically regulated ApiAP2 factors of the tachyzoite
(Fig. 1C) (21). AP2IX-4 mRNA and protein are dynamically expressed in the tachyzoite,
with peak expression occurring during the S phase and mitosis and cytokinesis; as
newly formed tachyzoites emerge (G1 phase), AP2IX-4 expression falls below detectable
limits.
To gain insight into the biological role of AP2IX-4, we generated knockout parasites
in both type I RH and type II Pru strains. Surprisingly, AP2IX-4 is not essential for
tachyzoite replication, indicating that its role is not in regulating the tachyzoite cell
cycle per se; however, this factor is required for efﬁcient bradyzoite development in vitro
and in vivo. These data indicate that AP2IX-4 could be required for regulating the
transition from the tachyzoite to bradyzoite. Previous studies have demonstrated that
spontaneous bradyzoite gene expression occurs during the S/M phase of the tachyzoite
cell cycle (21), and the prebradyzoite (SAG1-positive [SAG1]/BAG1) transitional
stages also show higher numbers of parasites with the characteristic genome content
of late S-phase/mitotic parasites (36). AP2IX-4 expression was detected in response to
alkaline stress in only a subpopulation of parasites (Fig. 4) that, based on costaining
with the daughter budding marker IMC3, were undergoing division. These AP2IX-4
vacuoles were also positive for Dolichos biﬂorus lectin staining, indicating that differ-
entiation of the tissue cyst was also under way (Fig. 4). These ﬁndings support the
long-held view that bradyzoite development is asynchronous compared to tachyzoite
replication (38, 39). The stochastic nature of bradyzoite development is not understood
in mechanistic terms; however, ApiAP2 factors such as AP2IX-4 now provide new
experimental avenues to help deﬁne the individual steps of tissue cyst differentiation
at the level of the individual parasite.
Transcriptome analysis of PruQap2IX-4 parasites shed further light on AP2IX-4
function. Consistent with a presumed lack of a role in tachyzoite cell division, no
signiﬁcant differences were determined between the Pru parent and AP2IX-4 knockout
tachyzoites (grown in normal pH 7.0 media). However, in response to alkaline stress,
numerous bradyzoite-speciﬁc mRNAs exhibited greatly enhanced expression when
AP2IX-4 was disrupted (Table 1), with the vast majority (~90%) of these gene expression
changes reversed following complementation. As only ~13% of encysted parasites
were expressing AP2IX-4 (Fig. 4), it is likely that the lack of synchronization in the
microarray study underestimated the magnitude and number of genes regulated by
this factor. Nevertheless, our transcriptomic analysis indicates that AP2IX-4 primarily
functions to repress a subset of bradyzoite genes during the early stages of bradyzoite
development. In addition to metabolic genes known to be speciﬁcally expressed in
the bradyzoite, AP2IX-4 may also control a novel, bradyzoite-speciﬁc CMGC (cyclin-
dependent kinase [CDK], mitogen-activated protein kinase [MAPK], glycogen synthase
kinase [GSK3], CDC-like kinase [CLK]) kinase that may play a role in stress-induced signal
transduction promoting latency. Altogether, these data reveal that what is distinctive
about AP2IX-4 is its role in balancing the induction of gene expression in stress-induced
bradyzoites, while having no apparent function in regulating gene expression speciﬁc
to the tachyzoite.
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This pattern of gene expression in AP2IX-4 knockout parasites is not the classic
proﬁle of a transcriptional repressor, where misexpression of bradyzoite genes in the
tachyzoite would be expected. In a separate study, we have identiﬁed a bradyzoite
transcriptional repressor in the tachyzoite that ﬁts this classic pattern (40).
Like AP2IX-4, AP2IV-4 exhibits peak expression in the tachyzoite S/M phase; how-
ever, dysregulated expression of bradyzoite-associated mRNAs in an AP2IV-4 knockout
occurs without stress. In contrast, AP2IX-4 may act as a passive repressor (i.e., it may
suppress transcription by competing with an activator for its target binding site) that
requires an additional protein induced by alkaline stress (41). Both types of repressors
(active and passive) are well documented among the AP2 transcription factors of plants
(41). Alternatively, AP2IX-4 could be a weak transcriptional activator that works in
conjunction with a stronger activator to express bradyzoite mRNAs at the proper level
and time. In the absence of AP2IX-4 to regulate a stronger transcription factor, the
timing of expression for a subset of bradyzoite-associated genes could become unbal-
anced, leading to the negative effects on tissue cyst development that we have
observed in vitro and in vivo. In addition, the unbalancing of gene expression during
bradyzoite development caused by the loss of AP2IX-4 could cause problems either
with tissue-speciﬁc formation of the tissue cyst or in achieving the proper escape from
the host immune system. Preventing the prearming of the immune system against the
parasite surviving to form the tissue cyst is a conﬁrmed function for AP2IV-4 (40) and
likely has driven the evolution of AP2IX-4 function. Validating this function will require
a complete dissection of the AP2IX-4 transcriptional mechanism and its molecular
partners during bradyzoite development in vitro and in vivo.
Our recent studies, and other investigations, have uncovered a number of ApiAP2s
that modulate gene expression associated with the developmental transition between
tachyzoites and bradyzoites. The AP2IX-4 studied here joins this list of factors. AP2IX-9
represses the expression of bradyzoite mRNAs; overexpression of AP2IX-9 promotes
tachyzoite growth during stress and prevents formation of tissue cysts (23). AP2IV-4 is
a cell cycle-regulated factor with peak expression in the tachyzoite S/M phase that also
suppresses bradyzoite gene expression (40). In contrast, AP2IV-3 is an activator of
bradyzoite gene expression; a knockout reduces tissue cyst formation, and its overex-
pression increases tissue cyst formation (26). Changes in bradyzoite gene expression
also occurred following the deletion of AP2XI-4, suggesting that this factor could be a
transcriptional activator of bradyzoite gene expression (24). Thus, the model emerging
from recent studies suggests that ApiAP2s act within a complex transcriptional network
comprised of activators and repressors that operate at the interface of tachyzoite
replication and bradyzoite conversion in order to control the intermediate life cycle.
The presence of multiple levels of ApiAP2 factor regulation in bradyzoite development
contrasts with the “master regulatory factor” model of gametogenesis of Plasmodium
falciparum (20). Toxoplasma has more than twice as many ApiAP2 factors as P. falci-
parum and a much larger number of hosts that can serve the Toxoplasma intermediate
life cycle. Consistent with this life cycle ﬂexibility, a recent analysis of ApiAP2 factor
expression revealed that a larger number of ApiAP2 factors are expressed in the
intermediate life cycle (26). Therefore, it is reasonable to suggest that the large diversity
of Toxoplasma ApiAP2 factors regulating bradyzoite development was necessary to
expand the host range of the intermediate life cycle. Future studies focused on how
Toxoplasma ApiAP2 factors function in different animal hosts will be important to
understand how these transcriptional mechanisms evolved.
MATERIALS AND METHODS
Parasite culture and growth assays. Parasite strains used in these studies included the RHku80::
HXGPRT (RHQ) and Pruku80hxgprt (PruQ) mutant strains (33, 42, 43). All parasites were cultured in
conﬂuent monolayers of human foreskin ﬁbroblasts (HFFs) using Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 1% and 5% heat-inactivated fetal bovine serum (FBS), respectively. Cultures
were maintained in humidiﬁed incubators at 37°C with 5% CO2. Parasite doubling assays were performed
as previously described (44). Brieﬂy, 106 freshly lysed tachyzoites were inoculated onto host cell
monolayers; after 24 h, the number of tachyzoites present within 50 random vacuoles was recorded at
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12-h intervals. For plaque assays, infected monolayers in 12-well plates were stained with crystal violet
to visualize and count plaques (45).
To initiate conversion to bradyzoites in vitro, type II parasites were allowed to invade HFF monolayers
for 4 h under normal culture conditions, and then the medium was replaced with alkaline RPMI medium
(pH 8.2) and the cultures were moved to a 37°C incubator with ambient CO2.
Generation of parasites expressing endogenously tagged AP2IX-4. RHQ parasites were engi-
neered to express endogenous AP2IX-4 tagged at its C terminus with three tandem copies of the
hemagglutinin (3xHA) epitope. Modiﬁcation of the endogenous genomic locus was achieved through
allelic replacement using parasites lacking KU80 to facilitate homologous recombination (42, 43). This
genetic “knock-in” approach employed the pLIC-3xHA plasmid, which contains a 1,514-bp sequence from
the AP2IX-4 locus for homologous recombination (Fig. 1), ampliﬁed with primers shown in Table S1 in
the supplemental material. This endogenous tagging construct also contains a modiﬁed dihydrofolate
reductase-thymidylate synthase (DHFR*-TS) minigene that confers resistance to pyrimethamine for
selection of transgenic parasites (46). Following drug selection, parasites were cloned by limiting dilution
in 96-well plates.
Generation of AP2IX-4 knockout parasites. Deletion of the AP2IX-4 gene was carried out in both
RHQ and PruQ parasites. To generate the ap2IX-4 clones, a plasmid was constructed that ﬂanked the
DHFR*-TS minigene with 1.6-kb to 1.9-kb sequences homologous to regions of the AP2IX-4 locus up- and
downstream of the coding region (Fig. 2A). This “knockout” plasmid was made using a MultiSite Gateway
three-fragment vector construction kit (Invitrogen) based on methods previously described (47). Two
entry vectors were constructed to include 5= and 3= ﬂanking sequences for recombination with the
endogenous locus: pDONR_P2R-P3 contained the 1,875-bp sequence downstream of the AP2IX-4
genomic sequence, and pDONR_P4P1R contained the 1,660-bp sequence upstream. A third entry vector,
pDONR221, was constructed to contain the DHFR*-TS minigene. Each entry vector was constructed using
the Gateway BP reaction, which consists of combining a PCR product with a pDONR vector; all primers
used to generate these vectors are listed in Table S1. The three entry vectors were combined in a
Gateway LR reaction with destination vector pDEST_R4R3 to create the ﬁnal knockout plasmids, which
were then electroporated into RHQ or PruQ parasites (45). Pyrimethamine-resistant parasites were cloned
by limiting dilution and examined by genomic PCR and RT-PCR to conﬁrm the ﬁdelity of each knockout
(Fig. 2B).
Complementation of the AP2IX-4 knockout. We complemented the PruQap2IX-4 parasites by
restoring a cDNA-derived version of AP2IX-4 at the knockout locus and downstream of its endogenous
promoter using single homologous recombination (Fig. 3A). A 2,116-bp sequence upstream of the start
codon was ampliﬁed (the primers are shown in Table S1) and ligated to a cDNA-derived AP2IX-4 coding
sequence using InFusion cloning (Clontech) and integrated at the PacI restriction site into vector
pLIC-3HA-HXGPRT. Vector pLIC-3HA-HXGPRT contains the HXGPRT drug selection cassette that replaced
the DHFR*-TS minigene of its parental vector, pLIC-3HA-DHFR. Integration of the AP2IX-4 coding
sequence into pLIC-3HA-HXGPRT fuses it to a C-terminal 3xHA tag. The resulting plasmid was electro-
porated into Δap2IX-4 parasites, which were then selected in 25 g/ml mycophenolic acid and 50 g/ml
xanthine and cloned by limiting dilution (48).
RT-PCR. Total RNA was isolated from the designated parasites using TRIzol reagent (Ambion) and
treatment with DNase I (Promega) for 30 min at 37°C. The mRNA was reverse transcribed using
Omniscript reverse transcriptase (Qiagen) and oligo(dT) primers per the manufacturer’s instructions;
subsequent PCRs were performed using primers for AP2IX-4 or GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) (Table S1).
Western blot analysis. Immunoblotting of parasite lysate was used to detect AP2IX-4 in various
clones by virtue of the 3xHA epitope tag. Parasite lysate was prepared in lysis buffer (150 mM NaCl,
50 mM Tris-Cl [pH 7.5], 0.1% NP-40) and sonicated prior to resolution on SDS-PAGE and transfer to a
nitrocellulose membrane. HA epitopes were detected using rat anti-HA antibody (Roche) at a 1:5,000
dilution followed by secondary probing with horseradish peroxidase (HRP)-conjugated goat anti-rat
antibody (GE Healthcare) at a 1:2,000 dilution. To ensure equal loading of samples, we also probed with
rabbit anti--tubulin antibody (kindly supplied by David Sibley, Washington University) at a 1:2,000
dilution followed by HRP-conjugated donkey anti-rabbit antibody (GE Healthcare) at a 1:2,000 dilution.
Immunoﬂuorescence assays (IFA). HFF monolayers grown on coverslips in 12-well plates were
inoculated with freshly lysed parasites. Infected monolayers were ﬁxed in 3% paraformaldehyde (PFA) for
10 min, quenched in 0.1 M glycine for 5 min, and then permeabilized with 0.3% Triton X-100 for 20 min
with blocking in 3% bovine serum albumin (BSA)–1 phosphate-buffered saline (PBS) for 30 min. For
IFAs of tachyzoite cultures, rabbit polyclonal anti-HA primary antibody (Invitrogen) was applied at a
1:2,000 dilution overnight at 4°C, followed by goat anti-rabbit Alexa Fluor 488 secondary antibody
(Thermo Fisher) at a 1:4,000 dilution. Detection of IMC3 was achieved using rat monoclonal anti-IMC3
antibody (kindly supplied by Marc-Jan Gubbels, Boston College) at a 1:2,000 dilution overnight at 4°C,
followed by goat anti-rat Alexa Fluor 594 antibody (Thermo Fisher) at a 1:4,000 dilution. 4=,6-Diamidino-
2-phenylindole (DAPI; Vector Laboratories) was applied for 5 min as a costain to visualize nuclei. For IFAs
of bradyzoite cultures, rat monoclonal anti-HA primary antibody (Roche) was applied at a 1:1,000 dilution
for 1 h at room temperature, followed by goat anti-rat Alexa Fluor 594 secondary antibody at a 1:1,000
dilution. For the visualization of tissue cyst walls, ﬂuorescein isothiocyanate (FITC)- or rhodamine-
conjugated Dolichos biﬂorus lectin (Vector Laboratories) was applied at a 1:1,000 dilution for 30 min at
room temperature or at a 1:250 dilution overnight at 4°C, respectively. In IFAs costained for IMC3 or
SAG1, rabbit polyclonal anti-HA primary antibody was applied at a 1:2,000 dilution, followed by goat
anti-rabbit Alexa Fluor 568 secondary antibody at a 1:4,000 dilution. Detection of IMC3 was achieved
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using rat monoclonal anti-IMC3 antibody at a 1:2,000 dilution overnight at 4°C, followed by either goat
anti-rat Alexa Fluor 647 antibody or goat anti-rat Alexa Fluor 594 antibody at a 1:4,000 dilution. Detection
of SAG1 was achieved using mouse monoclonal anti-SAG1 antibody (Abcam, Inc.) followed by goat
anti-mouse Alexa Fluor 647 secondary antibody.
RNA puriﬁcation and microarray analyses. Tachyzoite total RNA was puriﬁed from intracellular
PruQ or Δap2IX-4 parasites maintained at pH 7.0 (32 to 36 h postinfection) or PruQ, PruQΔap2IX-4, or
PruQΔap2IX-4::AP2IX-4HA parasites maintained at pH 8.2 (48 h) using an RNeasy minikit (Qiagen)
according to the manufacturer’s instructions. Intracellular tachyzoites or induced bradyzoites were
harvested by scraping the monolayer and passage of the culture through a syringe with a 27-gauge
needle. Host cell debris was excluded using a 3-m-pore-size ﬁlter for tachyzoites and a 5-m-pore-size
ﬁlter for bradyzoites. Two biological replicates were prepared for each parasite line under each set of
experimental conditions, and RNA quality was assessed using an Agilent Bioanalyzer 2100 (Santa Cruz,
CA). RNA samples were prepared for hybridization on a ToxoGeneChip as previously described (21).
Hybridization data were analyzed using the GeneSpring GX software package (v12.6.1; Agilent), and all
data sets have been made available in the NCBI GEO database. Transcriptome data from previous
publications were used to determine whether the genes in our data sets were associated with expression
in the bradyzoite stage (31, 49).
Virulence and cyst burden in infected mice. To examine acute virulence, 5-to-6-week-old female
BALB/c mice were injected intraperitoneally with 105, 106, or 107 parental PruQ, PruQap2IX-4, or
PruQap2IX-4::AP2IX-4HA parasites (8 mice per group). Plaque assays were performed for each sample
and ensured equal levels of viability between strains. Mice were examined daily, and time to death was
recorded. Serology performed on cardiac bleeds of infected mice conﬁrmed the presence of Toxoplasma.
To assess the cyst burden, mice were infected with 106 parasites as described above and allowed to
progress to chronic infection for 35 days (4 mice per group). Brains were then homogenized; homoge-
nates were ﬁxed, quenched, and permeabilized. Samples were blocked in 3% BSA–1 PBS–0.2% Triton
X-100. To visualize cyst walls, rhodamine-conjugated Dolichos biﬂorus lectin (Vector Laboratories) was
applied at a 1:250 dilution overnight at 4°C. Cyst quantiﬁcation was performed as previously described
(50).
Ethics statement.Mice were infected with Toxoplasma using an approved protocol (10852) from the
Institutional Animal Care and Use Committee (IACUC) of the Indiana University School of Medicine
(IUSM). The IUSM is accredited by the International Association for Assessment and Accreditation of
Laboratory Animal Care.
Accession number(s). All data sets from this work have been made available in the NCBI GEO
database (GSE94045).
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